RESPONSE TO THALIDOMIDE AND CYCLOSPORINE IN PATIENTS WITH LOWER-RISK MYELODYSPLASTIC SYNDROME WITHOUT ISOLATED DEL(5Q)

被引：1
|
作者：
Wang, J. [1 ]
Qin, T. [1 ]
Xu, Z. [1 ]
Zhang, Y. [1 ]
Gale, R. [2 ]
Fang, L. [1 ]
Zhang, H. [1 ]
Pan, L. [1 ]
Hu, N. [1 ]
Qu, S. [1 ]
Li, B. [1 ]
Xiao, Z. [1 ]
机构：
[1] Inst Hematol & Blood Dis Hosp, MDS & MPN Ctr, Tianjin, Peoples R China
[2] Univ London Imperial Coll Sci Technol & Med, Dept Med, London, England
来源：
LEUKEMIA RESEARCH | 2015年 / 39卷
关键词：
D O I：
10.1016/S0145-2126(15)30256-3
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
255
引用
收藏
页码：S127 / S127
页数：1
相关论文
共 50 条
  • [21] Bone marrow morphology in myelodysplastic syndrome associated with isolated del(5q)
    Naresh, Kikkeri N.
    Reid, Alistair
    AMERICAN JOURNAL OF HEMATOLOGY, 2010, 85 (08) : 609 - 610
  • [22] SURVIVAL OF PATIENTS WITH DE NOVO MYELODYSPLASTIC SYNDROME AND del(5q)
    Gritsaev, S. V.
    Martynkevich, I. S.
    Petrova, E. V.
    Martynenko, L. S.
    Kostroma, I. I.
    Ivanova, M. P.
    Tsybakova, N. Yu.
    Kozlovskaya, M. A.
    Sergeyev, A. N.
    Tiranova, S. A.
    Potikhonova, N. A.
    Abdulkadyrov, K. M.
    GEMATOLOGIYA I TRANSFUZIOLOGIYA, 2013, 58 (01): : 3 - 9
  • [23] Familial occurrence of myelodysplastic syndrome with del(5q)
    Volpicelli, Paola
    Latagliata, Roberto
    Carmosino, Ida
    Breccia, Massimo
    Vozella, Federico
    Mancini, Marco
    Cannella, Laura
    Alimena, Giuliana
    LEUKEMIA & LYMPHOMA, 2011, 52 (06) : 1143 - 1145
  • [24] CHARACTERIZATION OF THE TRANSCRIPTIONAL ALTERATIONS OF PATIENTS WITH DEL(5Q) MYELODYSPLASTIC SYNDROME
    Berastegui Zufiaurre, N.
    Serrano, G.
    Diaz Mazkiaran, A.
    Huerga, S.
    Garcia-Olloqui, P.
    Ainciburu, M.
    Alfonso, A.
    Vilas-Zornoza, A.
    San Martin, P.
    Lamo De Espinosa, J. M.
    Acha, P.
    Jimenez Solas, T.
    Molero, A.
    Montoro, M. J.
    Campelo, M.
    Valcarcel, D.
    Sole, F.
    Ochoa, I.
    Hernaez, M.
    Ezponda, T.
    Prosper, F.
    LEUKEMIA RESEARCH, 2023, 128
  • [25] Mechanisms of Resistance to Lenalidomide in Del(5q) Myelodysplastic Syndrome Patients
    Martinez-Hoyer, Sergio
    Docking, Rod
    Chan, Simon
    Jadersten, Martin
    Parker, Jeremy
    Karsan, Aly
    BLOOD, 2015, 126 (23)
  • [26] Higher-risk myelodysplastic syndromes with del(5q): does the del(5q) matter?
    Gorshein, Elan
    Weber, Urs M.
    Gore, Steven
    EXPERT REVIEW OF HEMATOLOGY, 2020, 13 (03) : 233 - 239
  • [27] Management of lower-risk myelodysplastic syndromes without del5q: current approach and future trends
    Stahl, Maximilian
    Zeidan, Amer M.
    EXPERT REVIEW OF HEMATOLOGY, 2017, 10 (04) : 345 - 364
  • [28] Stanozolol for the treatment of anemic lower-risk myelodysplastic syndromes without del(5q) after failure of epoetin alfa: findings from a retrospective study
    Wei-ying Qu
    Lin Zhao
    Xv-cheng Tan
    Yi-han Zhao
    Annals of Hematology, 2021, 100 : 1451 - 1457
  • [29] Stanozolol for the treatment of anemic lower-risk myelodysplastic syndromes without del(5q) after failure of epoetin alfa: findings from a retrospective study
    Qu, Wei-ying
    Zhao, Lin
    Tan, Xv-cheng
    Zhao, Yi-han
    ANNALS OF HEMATOLOGY, 2021, 100 (06) : 1451 - 1457
  • [30] Dual pyroptotic biomarkers predict erythroid response in lower-risk non-del(5q) myelodysplastic syndromes treated with lenalidomide and recombinant erythropoietin
    Wang, Chen
    McGraw, Kathy L.
    McLemore, Amy F.
    Komrokji, Rami
    Basiorka, Ashley A.
    Al Ali, Najla
    Lancet, Jeffrey E.
    Padron, Eric
    Kosmider, Olivier
    Fontenay, Michaela
    Fenaux, Pierre
    List, Alan F.
    Sallman, David A.
    HAEMATOLOGICA, 2022, 107 (03) : 737 - 739
12345